您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > APS-2-79
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
APS-2-79
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
APS-2-79图片
包装与价格:
包装价格(元)
5mg电议
25mg电议
100mg电议

产品介绍
APS-2-79 是一种 KSR 依赖性 MEK 拮抗剂。 APS-2-79 抑制 ATPbiotin 与 KSR2-MEK1 复合物中的 KSR2 结合,IC50 为 120 nM。 APS-2-79 使 KSR 非活性状态的稳定对抗致癌 Ras-MAPK 信号传导。

Cell experiment:

Cell viability assays are performed in 96 well plates. Optimal cell densities for 96 well plate assays are determined to obtain linear growth over the time course of assays. A549, HCT-116, A375, SK-MEL-239, COLO-205, LOVO, SK-MEL-2, CALU-6, MEWO, SW620 and SW1417 cells are plated at 500 cells per well and treated with inhibitors (e.g., APS-2-79; 100-3,000 nM) for 72hrs before measuring viability. H2087 and HEPG2 cells are plated at 2000 cells per well, and treated with inhibitors (e.g., APS-2-79; 100-3,000 nM) for 72hrs. Cell viability is measured using Resazurin, and the percent cell viability is determined by normalizing inhibitor-treated samples to DMSO controls[1].

产品描述

IC50: 120 nM

APS-2-79 is a KSR-dependent MAPK modulator.

Kinase suppressor of Ras (KSR), a MAPK scaffold, is subject to allosteric regulation via dimerization with RAF. Targeting of KSR has important therapeutic implications for cancer, however, testing this hypothesis is difficult due to the lack of small-molecule KSR antagonists.

In vitro: APS-2-79 was found to be able to suppress KSR-stimulated MEK and ERK phosphorylation. This MAPK signalling suppression caused by APS-2-79 was dependent on direct targeting of KSR as an active site mutant, which had been demonstrated to stimulate KSR-based MAPK outputs independent of ATP-binding, which could significantly diminish the activity of APS-2-79. Moreover, the KSR-stimulated MEK phosphorylation caused by RAF was reduced by the addition of APS-2-79 markedly. In addition, APS-2-79 was no effetive when KSR was absent or when the KSR2(A690F) mutant was used for in vitro assays, indicating that the activity of APS-2-79 was from direct targeting of KSR. However, APS-2-79 was found to lack direct activity against the highly homologous active RAF family kinases, such as recombinant BRAF and CRAF, or cellular BRAF(V600E) [1].

In vivo: So far, there is no animal in vivo data reported.

Clinical trial: Up to now, APS-2-79 is still in the preclinical development stage.

Reference:
[1] Dhawan NS, Scopton AP, Dar AC.  Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature. 2016 Sep 1;537(7618):112-116.